Dr. Piccart on a 4-Year Follow-Up of the NeoALTTO Trial

Martine Piccart, MD, PhD
Published: Tuesday, Jan 14, 2014

Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.

In the NeoALTTO trial, patients with HER2-positive breast cancer were randomly assigned to preoperative therapy with paclitaxel and lapatinib, paclitaxel and trastuzumab, or paclitaxel plus both anti-HER2 drugs. The overall goal of the trial was to determine whether pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival.

Overall, the primary endpoint of the trial was met, establishing a significant connection between pCR and survival. Patients who achieved a pCR were 62% less likely to experience a cancer-related event, Piccart states. Moreover, pCR was associated with a 67% reduction in the risk of death. Taken together, these findings confirm that pCR is an acceptable surrogate endpoint, Piccart believes.


Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, gives an update on a four-year follow-up analysis of the NeoALTTO trial.

In the NeoALTTO trial, patients with HER2-positive breast cancer were randomly assigned to preoperative therapy with paclitaxel and lapatinib, paclitaxel and trastuzumab, or paclitaxel plus both anti-HER2 drugs. The overall goal of the trial was to determine whether pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival.

Overall, the primary endpoint of the trial was met, establishing a significant connection between pCR and survival. Patients who achieved a pCR were 62% less likely to experience a cancer-related event, Piccart states. Moreover, pCR was associated with a 67% reduction in the risk of death. Taken together, these findings confirm that pCR is an acceptable surrogate endpoint, Piccart believes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x